Thursday, 21 February 2019 12:04

2019 CPMA Elimination Guidelines

Written by Collin Baird, (AAFC/AAC)
Rate this item
(0 votes)

The Canadian Pari-Mutuel Agency (CPMA) is pleased to advise the Canadian horseracing industry that a new edition of the CPMA Elimination Guidelines will be published in March 2019. The new elimination guidelines will come into force on April 1, 2019. The following is a summary of the changes, sorted into five categories:

  1.        Substances completely removed from the guidelines:
    •       These substances have been removed because no Health Canada approved product is available or veterinary use of the substance is no longer recommended;
    •       These substances remain prohibited under the Pari-Mutuel Betting Supervision Regulations ;
    •       Testing of official samples for the presence of these substances will continue;
    •       Guidance on elimination will no longer be provided; and
    •       Use of any of these substances, including in compounded form, may result in a positive test.
Acetaminophen Fenoterol Phenothiazine
Aminocaproic acid Floctafenine Piroxicam
Carbazochrome Flurbiprofen Reserpine
Chloroprocaine Ibuprofen Salmeterol
Chloropheniramine Indapamide Sulindac
Chlorpromazine Indomethacin Tenoxicam
Cromoglycate Meclofenamic acid Tiaprofenic acid
Diflunisal Mefenamic acid Tripelennamine
Dyphylline Nedocromil Vedaprofen
Ergonovine Oxaprozin Zompirac
Ethacrynic acid Pentazocine  
Etodolac Pentoxifylline  
  1.        Substances with some doses and routes of administration removed from the guidelines:
    •       Testing of official samples for the presence of these substances will be based ONLY on the doses and routes included in the guidelines;
    •       No elimination guidelines will be provided for doses and routes contained in previous editions of the guidelines; and
    •       Use of doses and routes for any of the substances that are not included in the guidelines may result in a positive test.
DRUG CHANGE
Dembrexine Removal of guidance for single administration
Diclofenac Removal of guidance for oral use
Ephedrine Removal of guidance for 300 mg oral dose
Flunixin Removal of guidance for oral and intramuscular use
Guaifenesin Removal of guidance for oral use
Hydrochlorothiazide Removal of guidance for intravenous use
Hyocine butylbromide Removal of guidance for oral use
Mepivacaine Removal of guidance for intra-articular use
Penicillin G procaine Removal of guidance for oral and topical uses
Phenylbutazone Removal of guidance for 3g oral regimen and both 3g IV doses
Salicylic acid Removal of guidance for 3.35g and 8.38g topical doses
Trichlormethiazide Removal of guidance for intravenous use
  1.        Substances with modified elimination guidelines (some doses and routes):
    •       Testing of official samples for the presence of these substances will be based on the elimination guidelines included in the new edition of the guidelines; and
    •       Use of any of these substances outside the published elimination guidelines may result in a positive test.
DRUG CHANGE
Clenbuterol Elimination guidance extended from 7 days to 21 days
Dantrolene Increase from 1g oral/single dose/36 h to 1.5g oral/single dose/48 h
Isoflupredone Decrease intramuscular dose from 24 mg to 20 mg
Phenylbutazone Elimination guidance for 2g doses extended from 48 h to 96 h
Pyrilamine Elimination guidance for 750 mg oral dose extended from 36 h to 48 h
Triamcinolone acetonide Elimination guidance for intra-articular use extended from 6 days to 10 days
Trichlormethiazide Elimination guidance for oral and intramuscular doses all extended to 48 h
  1.        Substances added to the 2019 edition of the guidelines:
DRUG CHANGE
Cetirizine1 200 mg oral/single dose/72 h
Clodronate2 720 mg intramuscular/single dose/30 days
Fluticasone 2 mg aerosol/twice daily for 7 days/24 h
Fluticasone/Salmeterol 2.5 mg & 250 µg aerosol/twice daily for 7 days/24 h
Ipratropium bromide 0.18 mg aerosol/once daily for 3 days/24 h

 

1 Note that concurrent administration of cetirizine and oral ivermectin will significantly increase the elimination time of cetirizine.

2 Applies to horses 4 years of age and older. For more details, see CPMA Industry Notification dated May 31, 2018, “Addition of clodronate and tiludronate to the Schedule of Prohibited Drugs in the Pari-Mutuel Betting Supervision Regulations.”

  1.        Substances with some doses and routes added to the 2019 edition of the guidelines:
DRUG CHANGE
Dexamethasone 20 mg intramuscular/single dose/48 h
Isoflupredone 10 mg intra-articular/single dose/ 6 days
Triamcinolone acetonide 10 mg topical/single dose/24 h
Triamcinolone acetonide 10 mg intramuscular/single dose/10 days

The CPMA strongly recommends that your veterinarian be consulted on any decision to administer any supplement or medication to a horse.

To order booklet copies of the Elimination Guidelines 2019 or should you have any questions or concerns regarding the above or any other pari-mutuel betting matter, please do not hesitate to contact the CPMA by telephone at 1-800-268-8835, or by email at This email address is being protected from spambots. You need JavaScript enabled to view it..

Read 238 times Last modified on Thursday, 21 February 2019 12:29